Thyrocare exits imaging with ₹141.40 crore Nueclear sale

₹141.40 crore is the approximate total consideration for Thyrocare Technologies’ sale of 100% of Nueclear Healthcare Limited.

₹20.59 crore is the separate consideration for laboratory properties Thyrocare will buy from Nueclear in Gurugram and Hyderabad.

Reader Takeaway: Pathology focus improves capital allocation; completion still depends on shareholder approval and transaction conditions.

What just happened

Thyrocare Technologies has approved the sale of its entire shareholding in material wholly owned subsidiary Nueclear Healthcare Limited to Trovera Healthcare Private Limited.

The consideration is split into ₹81.90 crore of cash, subject to working-capital adjustments, and ₹59.50 crore through 42,500 compulsorily convertible preference shares of Trovera priced at ₹14,000 each.

The transaction values the total consideration at approximately ₹141.40 crore.

Why this matters

The deal removes Thyrocare from the radiology and diagnostic imaging business and concentrates management attention and capital on pathology, its core operating segment.

Nueclear contributed ₹44.62 crore of turnover in FY2026, equal to 5.38% of Thyrocare’s consolidated turnover. Its net worth stood at ₹83.55 crore, representing 14.27% of consolidated net worth.

That makes the divestment meaningful for the balance sheet even though the subsidiary contributes a relatively modest share of consolidated revenue.

What changes now

Before or alongside the divestment, Thyrocare will acquire land and buildings from Nueclear for ₹20.59 crore. These properties house diagnostic laboratory facilities at Gurugram and Hyderabad.

The property transaction allows Thyrocare to retain ownership of operating premises that remain relevant to its continuing business after the subsidiary sale. The company has described the purchase as an arm’s-length related-party transaction.

Strategic rationale

Management said radiology and diagnostic imaging require continuing investment in equipment, technology and infrastructure.

By exiting the business, Thyrocare intends to direct capital and management bandwidth toward pathology, where its operating model is more closely aligned with the company’s core strategy.

The structure also means shareholders should look beyond the headline ₹141.40 crore value. Only ₹81.90 crore is cash consideration, while ₹59.50 crore will be received through Trovera CCPS.

Risks to watch

The sale is board-approved but is not yet complete. Shareholder approval is required under Regulation 37A of the SEBI Listing Obligations and Disclosure Requirements Regulations.

The cash component remains subject to working-capital adjustments, so the final cash received may differ from the stated ₹81.90 crore.

The transaction is expected to close on or before November 30, 2026, subject to conditions precedent and required approvals.

What to track next

Investors should watch shareholder approval, final transaction closure, working-capital adjustments and the treatment of the ₹59.50 crore Trovera CCPS.

The next key question is how effectively Thyrocare redeploys capital from the imaging exit into its pathology business and whether the sharper focus improves returns over time.